754 related articles for article (PubMed ID: 17308267)
21. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer.
Lidgren M; Jönsson B; Rehnberg C; Willking N; Bergh J
Ann Oncol; 2008 Mar; 19(3):487-95. PubMed ID: 18065409
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis.
Norum J; Olsen JA; Wist EA; Lønning PE
Acta Oncol; 2007; 46(2):153-64. PubMed ID: 17453363
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
[TBL] [Abstract][Full Text] [Related]
25. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
26. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
Naeim A; Keeler EB
Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
[TBL] [Abstract][Full Text] [Related]
27. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
[TBL] [Abstract][Full Text] [Related]
28. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
29. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.
Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
Breast Cancer Res Treat; 2008 Jun; 109(3):559-66. PubMed ID: 17661170
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
Au HJ; Golmohammadi K; Younis T; Verma S; Chia S; Fassbender K; Jacobs P
Breast Cancer Res Treat; 2009 Apr; 114(3):579-87. PubMed ID: 18443903
[TBL] [Abstract][Full Text] [Related]
31. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
[TBL] [Abstract][Full Text] [Related]
32. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
33. Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context.
Wu B; Ye M; Chen H; Shen JF
Clin Ther; 2012 Feb; 34(2):468-79. PubMed ID: 22325735
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
36. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer.
Perez-Ellis C; Goncalves A; Jacquemier J; Marty M; Girre V; Roché H; Brain E; Moatti JP; Viens P; Le Corroller-Soriano AG
Am J Clin Oncol; 2009 Oct; 32(5):492-8. PubMed ID: 19487912
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].
Sawaki M; Tokudome N; Mizuno T; Nakayama T; Taira N; Bando H; Murakami S; Yamamoto Y; Kashiwaba M; Iwata H; Uemura Y; Ohashi Y
Jpn J Clin Oncol; 2011 May; 41(5):709-12. PubMed ID: 21355003
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt.
Elsisi GH; Nada Y; Rashad N; Carapinha J; Noor AO; Almasri DM; Zaidy MA; Foad A; Khaled H
J Med Econ; 2020 Jun; 23(6):575-580. PubMed ID: 32011199
[No Abstract] [Full Text] [Related]
40. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
